US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cartesian Therapeutics

6.88

-0.0200-0.29%

Post-market: 6.880.00000.00%17:01 EST

Volume:126.14K

Turnover:876.06K

Market Cap:178.90M

PE:-3.67

High:7.08

Open:6.93

Low:6.80

Close:6.90

52wk High:26.50

52wk Low:5.98

Shares:26.00M

Float Shares:9.39M

Volume Ratio:0.53

T/O Rate:1.34%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8750

EPS(LYR):-4.4814

ROE:-7029.26%

ROA:-12.67%

PB:-4.99

PE(LYR):-1.54

Loading ...

Overview Company News Filings

Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.

H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)

Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA) and Cartesian Therapeutics (RNAC)

Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

Wedbush Remains a Buy on Cartesian Therapeutics (RNAC)

Top Calls on Wall Street: Nvidia, Applied Materials, Nu Holdings, Lowe's, Shake Shack, Gap & More

Tiger Newspress

Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating

Cartesian Therapeutics Is Maintained at Buy by BTIG

Cartesian Therapeutics price target raised to $44 from $42 at BTIG

Cartesian Therapeutics Reports Q3 2025 Financial Results

Cartesian Therapeutics Reports Promising Phase 2 Trial Results

Cartesian Therapeutics Inc - Cartesian Plans to Pause Further Development of Descartes-08 in Sle

THOMSON REUTERS

Cartesian: Myositis Seamless Adaptive Clinical Trial Design Provides Potential Opportunity for Single Pivotal Trial Expected to Commence in 1H26

THOMSON REUTERS

Cartesian - 100% Lldas Response Rate Observed in Patients With Sle Who Got Descartes-08 in Phase 2 Open-Label Trial Reaching Month 3 Follow-up

THOMSON REUTERS

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

Recent 11% pullback would hurt Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Cartesian Therapeutics (RNAC) and Anixa Biosciences (ANIX)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RNAC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNAC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","market":"US","secType":"STK","nameCN":"Cartesian Therapeutics","latestPrice":6.88,"timestamp":1764968400000,"preClose":6.9,"halted":0,"volume":126141,"hourTrading":{"tag":"盘后","latestPrice":6.88,"preClose":6.88,"latestTime":"17:01 EST","volume":181,"amount":1245.28,"timestamp":1764972086346},"delay":0,"floatShares":9390341,"shares":26003606,"eps":-1.874951,"marketStatus":"Market Closed","change":-0.02,"latestTime":"12-05 16:00:00 EST","open":6.93,"high":7.075,"low":6.8001,"amount":876061.6572744,"amplitude":0.039841,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.874951,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1466568000000,"exchange":"NASDAQ","adjPreClose":6.9,"postHourTrading":{"tag":"盘后","latestPrice":6.88,"preClose":6.88,"latestTime":"17:01 EST","volume":181,"amount":1245.28,"timestamp":1764972086346},"volumeRatio":0.5319244940944375,"impliedVol":1.1029,"impliedVolPercentile":0.8148},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","floatShares":9390341,"roa":"-12.67%","roe":"-7029.26%","lyrEps":-4.481379,"volumeRatio":0.5319244940944375,"shares":26003606,"dividePrice":0,"high":7.075,"amplitude":0.039841,"preClose":6.9,"low":6.8001,"week52Low":5.98,"pbRate":"-4.99","psRate":"163.98","week52High":26.5,"institutionHeld":0,"latestPrice":6.88,"eps":-1.874951,"divideRate":0,"volume":126141,"delay":0,"ttmEps":-1.874951,"open":6.93,"prevYearClose":17.91,"prevWeekClose":7.49,"prevMonthClose":7.49,"prevQuarterClose":10.22,"fiveDayClose":7.49,"twentyDayClose":7.55,"sixtyDayClose":9.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNAC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"RNAC","fiscalQuarterEnding":"2025/09","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-1.38},{"market":"US","date":"2025-08-07","symbol":"RNAC","fiscalQuarterEnding":"2025/06","expectedEps":-0.76,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":0.5},{"market":"US","date":"2025-05-08","symbol":"RNAC","fiscalQuarterEnding":"2025/03","expectedEps":-0.61,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-13","symbol":"RNAC","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"pre","actualEps":-2.4},{"market":"US","date":"2024-11-07","symbol":"RNAC","fiscalQuarterEnding":"2024/09","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.69}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNAC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNAC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.4444,"hold":0.2222,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4444,"analysts":9,"updateTime":1752037200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNAC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNAC","date":"2025-12-05","current":-3.669429,"percent":0.437923,"low":-14.109752,"twenty":-7.06451,"median":-2.365337,"eighty":-1.65105,"high":-0.322359,"avg":-4.150536,"sd":3.178917,"marketCap":179424881},"quantilePoints":[{"date":"2024-02-09","current":-12.195228,"twenty":-12.293822,"median":-12.139657,"eighty":-11.530164,"marketCap":110159496},{"date":"2024-02-16","current":-13.543282,"twenty":-12.82193,"median":-12.371802,"eighty":-12.018117,"marketCap":122336468},{"date":"2024-02-23","current":-12.9069,"twenty":-13.170416,"median":-12.72226,"eighty":-12.169773,"marketCap":116588031},{"date":"2024-03-01","current":-13.113052,"twenty":-13.187625,"median":-12.9069,"eighty":-12.193077,"marketCap":118450201},{"date":"2024-03-08","current":-0.474472,"twenty":-13.096919,"median":-12.72226,"eighty":-12.104521,"marketCap":104246325},{"date":"2024-03-15","current":-0.394571,"twenty":-13.085087,"median":-12.369113,"eighty":-0.499332,"marketCap":86691095},{"date":"2024-03-22","current":-0.518772,"twenty":-13.077916,"median":-12.18985,"eighty":-0.473381,"marketCap":113979437},{"date":"2024-03-28","current":-0.486782,"twenty":-13.018401,"median":-12.095738,"eighty":-0.472836,"marketCap":106950867},{"date":"2024-04-05","current":-0.371573,"twenty":-12.924109,"median":-11.522994,"eighty":-0.462369,"marketCap":81638284},{"date":"2024-04-12","current":-1.459867,"twenty":-12.9069,"median":-1.226402,"eighty":-0.444134,"marketCap":320747357},{"date":"2024-04-19","current":-1.398365,"twenty":-12.846668,"median":-1.459867,"eighty":-0.462369,"marketCap":307234719},{"date":"2024-04-26","current":-1.691309,"twenty":-12.729072,"median":-1.487381,"eighty":-0.467868,"marketCap":371597548},{"date":"2024-05-03","current":-1.978779,"twenty":-12.63227,"median":-1.536745,"eighty":-0.471303,"marketCap":434757574},{"date":"2024-05-10","current":-1.526348,"twenty":-12.47667,"median":-1.594687,"eighty":-0.472836,"marketCap":389021718},{"date":"2024-05-17","current":-1.839158,"twenty":-12.299559,"median":-1.62026,"eighty":-0.47633,"marketCap":468748036},{"date":"2024-05-24","current":-1.777713,"twenty":-12.193077,"median":-1.671483,"eighty":-0.482182,"marketCap":453087509},{"date":"2024-05-31","current":-2.195259,"twenty":-12.18985,"median":-1.697348,"eighty":-0.489671,"marketCap":559507906},{"date":"2024-06-07","current":-2.422885,"twenty":-12.179811,"median":-1.717665,"eighty":-0.504164,"marketCap":617523039},{"date":"2024-06-14","current":-2.045138,"twenty":-12.139657,"median":-1.777713,"eighty":-0.515905,"marketCap":521246392},{"date":"2024-06-21","current":-1.598266,"twenty":-12.069386,"median":-1.728138,"eighty":-0.518199,"marketCap":407351653},{"date":"2024-06-28","current":-1.991374,"twenty":-11.947846,"median":-1.777713,"eighty":-0.520305,"marketCap":507543431},{"date":"2024-07-05","current":-1.23169,"twenty":-11.531957,"median":-1.728138,"eighty":-0.526438,"marketCap":313922113},{"date":"2024-07-12","current":-1.241477,"twenty":-11.522994,"median":-1.709478,"eighty":-0.530124,"marketCap":316416386},{"date":"2024-07-15","current":-1.240079,"twenty":-9.729226,"median":-1.703386,"eighty":-0.53751,"marketCap":316060062},{"date":"2024-08-02","current":-1.081399,"twenty":-7.935458,"median":-1.699966,"eighty":-0.544895,"marketCap":275617201},{"date":"2024-08-09","current":-1.198323,"twenty":-2.548847,"median":-1.676743,"eighty":-0.772791,"marketCap":275192581},{"date":"2024-08-16","current":-1.345437,"twenty":-2.529995,"median":-1.625846,"eighty":-1.101689,"marketCap":308976908},{"date":"2024-08-23","current":-1.244878,"twenty":-2.507232,"median":-1.598266,"eighty":-1.148418,"marketCap":285883824},{"date":"2024-08-30","current":-1.388267,"twenty":-2.46827,"median":-1.531547,"eighty":-1.172903,"marketCap":318812851},{"date":"2024-09-06","current":-1.307262,"twenty":-2.424002,"median":-1.519153,"eighty":-1.173531,"marketCap":300210089},{"date":"2024-09-13","current":-1.496275,"twenty":-2.390626,"median":-1.497092,"eighty":-1.177113,"marketCap":343616533},{"date":"2024-09-20","current":-1.540036,"twenty":-2.248325,"median":-1.497406,"eighty":-1.182548,"marketCap":353666301},{"date":"2024-09-27","current":-1.616387,"twenty":-2.173184,"median":-1.49772,"eighty":-1.183457,"marketCap":371199939},{"date":"2024-10-04","current":-2.374287,"twenty":-2.173184,"median":-1.519153,"eighty":-1.187433,"marketCap":545250240},{"date":"2024-10-11","current":-2.176603,"twenty":-2.352646,"median":-1.530726,"eighty":-1.193387,"marketCap":499852543},{"date":"2024-10-18","current":-2.257757,"twenty":-2.310612,"median":-1.544226,"eighty":-1.200277,"marketCap":518489492},{"date":"2024-10-25","current":-2.299664,"twenty":-2.339564,"median":-1.569114,"eighty":-1.208188,"marketCap":528113202},{"date":"2024-10-31","current":-2.199769,"twenty":-2.325678,"median":-1.616387,"eighty":-1.208566,"marketCap":505172538},{"date":"2024-11-08","current":-2.028231,"twenty":-2.320475,"median":-1.625846,"eighty":-1.217877,"marketCap":496569789},{"date":"2024-11-15","current":-1.766791,"twenty":-2.31186,"median":-1.676743,"eighty":-1.221601,"marketCap":432561563},{"date":"2024-11-22","current":-1.725268,"twenty":-2.307988,"median":-1.693927,"eighty":-1.221601,"marketCap":422395604},{"date":"2024-11-29","current":-1.954681,"twenty":-2.306323,"median":-1.709478,"eighty":-1.229672,"marketCap":478562529},{"date":"2024-12-06","current":-2.388593,"twenty":-2.306323,"median":-1.725268,"eighty":-1.23169,"marketCap":584796802},{"date":"2024-12-13","current":-2.088591,"twenty":-2.321516,"median":-1.757967,"eighty":-1.238401,"marketCap":511347747},{"date":"2024-12-20","current":-2.024787,"twenty":-2.313583,"median":-1.76875,"eighty":-1.241197,"marketCap":495726646},{"date":"2024-12-27","current":-2.088883,"twenty":-2.309537,"median":-1.777713,"eighty":-1.243092,"marketCap":511419083},{"date":"2025-01-03","current":-1.778913,"twenty":-2.307156,"median":-1.777862,"eighty":-1.244452,"marketCap":435529430},{"date":"2025-01-10","current":-1.777862,"twenty":-2.305849,"median":-1.777862,"eighty":-1.244878,"marketCap":435272177},{"date":"2025-01-17","current":-1.989062,"twenty":-2.304427,"median":-1.779554,"eighty":-1.246554,"marketCap":486980042},{"date":"2025-01-24","current":-2.040548,"twenty":-2.299664,"median":-1.784789,"eighty":-1.253258,"marketCap":499585442},{"date":"2025-01-31","current":-2.036345,"twenty":-2.283748,"median":-1.80308,"eighty":-1.272811,"marketCap":498556430},{"date":"2025-02-07","current":-1.976453,"twenty":-2.276485,"median":-1.8278,"eighty":-1.28026,"marketCap":483893005},{"date":"2025-02-14","current":-1.999569,"twenty":-2.273364,"median":-1.845442,"eighty":-1.299813,"marketCap":489552573},{"date":"2025-02-21","current":-2.060513,"twenty":-2.263946,"median":-1.859179,"eighty":-1.303538,"marketCap":504473250},{"date":"2025-02-28","current":-1.892393,"twenty":-2.258524,"median":-1.87682,"eighty":-1.306703,"marketCap":463312761},{"date":"2025-03-07","current":-1.875581,"twenty":-2.211367,"median":-1.875581,"eighty":-1.307262,"marketCap":459196712},{"date":"2025-03-14","current":-5.557927,"twenty":-2.211367,"median":-1.881886,"eighty":-1.317995,"marketCap":430316947},{"date":"2025-03-21","current":-5.33039,"twenty":-2.277938,"median":-1.88594,"eighty":-1.323353,"marketCap":412700118},{"date":"2025-03-28","current":-4.805047,"twenty":-2.306323,"median":-1.893969,"eighty":-1.325512,"marketCap":372025970},{"date":"2025-04-04","current":-4.129128,"twenty":-2.32984,"median":-1.905491,"eighty":-1.337057,"marketCap":319693626},{"date":"2025-04-11","current":-3.466594,"twenty":-2.375387,"median":-1.926854,"eighty":-1.34432,"marketCap":268397566},{"date":"2025-04-17","current":-3.536863,"twenty":-2.423443,"median":-1.931271,"eighty":-1.357169,"marketCap":273838057},{"date":"2025-04-25","current":-4.03209,"twenty":-2.511189,"median":-1.940728,"eighty":-1.376163,"marketCap":312180567},{"date":"2025-05-02","current":-4.105705,"twenty":-2.552358,"median":-1.945456,"eighty":-1.384171,"marketCap":317880129},{"date":"2025-05-09","current":-7.05935,"twenty":-3.360856,"median":-1.954681,"eighty":-1.385102,"marketCap":270443712},{"date":"2025-05-16","current":-7.066125,"twenty":-3.485332,"median":-1.967259,"eighty":-1.38715,"marketCap":270703255},{"date":"2025-05-23","current":-6.195562,"twenty":-3.649293,"median":-1.975402,"eighty":-1.394326,"marketCap":237351991},{"date":"2025-05-30","current":-6.774808,"twenty":-3.931706,"median":-1.977504,"eighty":-1.416672,"marketCap":259542910},{"date":"2025-06-06","current":-6.327671,"twenty":-4.025398,"median":-1.983808,"eighty":-1.446219,"marketCap":242413077},{"date":"2025-06-13","current":-6.937404,"twenty":-4.149205,"median":-1.989062,"eighty":-1.451731,"marketCap":265771939},{"date":"2025-06-20","current":-6.774808,"twenty":-4.316511,"median":-1.991374,"eighty":-1.456219,"marketCap":259542910},{"date":"2025-06-27","current":-7.76393,"twenty":-4.826462,"median":-1.999044,"eighty":-1.463428,"marketCap":297436174},{"date":"2025-07-03","current":-7.59456,"twenty":-4.979046,"median":-2.003247,"eighty":-1.47767,"marketCap":290947602},{"date":"2025-07-11","current":-9.173091,"twenty":-5.33039,"median":-2.020584,"eighty":-1.478169,"marketCap":351421100},{"date":"2025-07-18","current":-8.488835,"twenty":-5.941507,"median":-2.024838,"eighty":-1.490688,"marketCap":325207266},{"date":"2025-07-25","current":-9.118892,"twenty":-6.287022,"median":-2.028231,"eighty":-1.49255,"marketCap":349344756},{"date":"2025-08-01","current":-8.67853,"twenty":-6.612213,"median":-2.031821,"eighty":-1.496275,"marketCap":332474467},{"date":"2025-08-08","current":-7.544353,"twenty":-6.70706,"median":-2.036345,"eighty":-1.497092,"marketCap":273558227},{"date":"2025-08-15","current":-8.196452,"twenty":-6.774808,"median":-2.042843,"eighty":-1.49772,"marketCap":297203340},{"date":"2025-08-22","current":-7.859415,"twenty":-6.950953,"median":-2.051056,"eighty":-1.50093,"marketCap":284982380},{"date":"2025-08-29","current":-7.371787,"twenty":-7.039026,"median":-2.060422,"eighty":-1.518941,"marketCap":267300991},{"date":"2025-09-05","current":-7.170999,"twenty":-7.05935,"median":-2.070182,"eighty":-1.51928,"marketCap":260020420},{"date":"2025-09-12","current":-7.142315,"twenty":-7.086783,"median":-2.081446,"eighty":-1.524951,"marketCap":258980338},{"date":"2025-09-19","current":-7.3933,"twenty":-7.086783,"median":-2.084663,"eighty":-1.52985,"marketCap":268081053},{"date":"2025-09-26","current":-6.783765,"twenty":-7.148052,"median":-2.088591,"eighty":-1.535541,"marketCap":245979317},{"date":"2025-10-03","current":-7.414813,"twenty":-7.201117,"median":-2.095187,"eighty":-1.539378,"marketCap":268861114},{"date":"2025-10-10","current":-7.242709,"twenty":-7.224056,"median":-2.14643,"eighty":-1.54674,"marketCap":262620624},{"date":"2025-10-17","current":-6.755081,"twenty":-7.209722,"median":-2.173618,"eighty":-1.557355,"marketCap":244939235},{"date":"2025-10-24","current":-6.453899,"twenty":-7.201117,"median":-2.199769,"eighty":-1.567209,"marketCap":234018378},{"date":"2025-10-31","current":-5.81568,"twenty":-7.176736,"median":-2.267478,"eighty":-1.592436,"marketCap":210876560},{"date":"2025-11-07","current":-4.091695,"twenty":-7.170999,"median":-2.283748,"eighty":-1.612763,"marketCap":196315417},{"date":"2025-11-14","current":-3.918507,"twenty":-7.148052,"median":-2.305763,"eighty":-1.619485,"marketCap":188006071},{"date":"2025-11-21","current":-3.875149,"twenty":-7.086783,"median":-2.31186,"eighty":-1.622774,"marketCap":185925782},{"date":"2025-11-28","current":-4.059422,"twenty":-7.068835,"median":-2.325678,"eighty":-1.626335,"marketCap":194767008},{"date":"2025-12-05","current":-3.739654,"twenty":-7.06451,"median":-2.365337,"eighty":-1.65105,"marketCap":179424881}],"updateTime":1765117215357},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNAC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2585707128","title":"Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2585707128","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585707128?lang=en_us&edition=fundamental","pubTime":"2025-11-22 03:15","pubTimestamp":1763752523,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on RNAC stock, giving a Buy rating on November 19. Tyler Van Buren has given h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-pivot-and-promising-clinical-data-justify-buy-rating-for-cartesian-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-pivot-and-promising-clinical-data-justify-buy-rating-for-cartesian-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2584229829","title":"Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2584229829","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584229829?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:41","pubTimestamp":1763574060,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Cartesian Therapeutics Inc ::*CARTESIAN THERAPEUTICS ANNOUNCES STRONG EFFICACY SIGNAL IN PHASE 2 TRIAL OF DESCARTES-08 IN PATIENTS WITH SLE AND EXPANSION OF CLINICAL DEVELOPMENT INT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2K1SXx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2584493019","title":"Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2584493019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584493019?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:48","pubTimestamp":1763556480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 07:48 ET (12:48 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2584126948","title":"H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’","url":"https://stock-news.laohu8.com/highlight/detail?id=2584126948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584126948?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:15","pubTimestamp":1763550925,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $30 from $40 and keeps a Buy rating on the shares. The firm say...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-cuts-cartesian-target-calls-shares-mispriced-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-cuts-cartesian-target-calls-shares-mispriced-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2584963286","title":"Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584963286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584963286?lang=en_us&edition=fundamental","pubTime":"2025-11-19 04:30","pubTimestamp":1763497819,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Cartesian Therapeutics (RNAC – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cartesian-therapeutics-rnac-and-galmed-pharmaceuticals-glmd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cartesian-therapeutics-rnac-and-galmed-pharmaceuticals-glmd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","RNAC","XBI","BK4588","BK4137","BK4139","HCSG","LABU","LU0029874061.USD","LU0128526141.USD","GLMD","BK4581","BK4585"],"gpt_icon":0},{"id":"2584262466","title":"Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA) and Cartesian Therapeutics (RNAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584262466","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584262466?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:30","pubTimestamp":1763386222,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Athira Pharma (ATHA – Research Report) and Cartesian Therapeutics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-athira-pharma-atha-and-cartesian-therapeutics-rnac-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-athira-pharma-atha-and-cartesian-therapeutics-rnac-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","RNAC","ATHA","LABU","XLV","BK4007","BK4588","BK4581","HCSG","BK4137","LU0128526141.USD","BK4585","XBI","BK4139"],"gpt_icon":0},{"id":"2583685787","title":"Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2583685787","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583685787?lang=en_us&edition=fundamental","pubTime":"2025-11-15 02:02","pubTimestamp":1763143320,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics, Inc.  on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus .SLE is a chronic autoimmune disease where the body’s immune system attacks healthy tissues and organs, causing inflammation in various parts of the body, including joints, skin, kidneys, and the brain.Initial data reported a significant reduction in disease activity following initial Descartes-08 treatment, with 100% of participants who reached Month 3 follow-up (n=3) achieving Lupus Low Disease Activity State response.Disease remission was seen in 2 out of 3 participants at Month 3.At this time, Cartesian plans to pause further development of Descartes-08 in SLE, including enrollment in the Phase 2 trial, to prioritize the opportunities in myasthenia gravis, currently in Phase 3, and myositis.Cartesian announced the planned expansion of Descartes-08 into myositis.In this trial, no significant adverse e","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/14/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/14/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48873824/cartesian-pauses-lupus-and-multiple-myeloma-studies-as-it-shifts-development-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4077","RNAC","SLE","BK4139"],"gpt_icon":0},{"id":"2583825683","title":"Wedbush Remains a Buy on Cartesian Therapeutics (RNAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583825683","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583825683?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:55","pubTimestamp":1763139359,"startTime":"0","endTime":"0","summary":"In a report released today, Martin Fan from Wedbush maintained a Buy rating on Cartesian Therapeutics, with a price target of $38.00. Fan covers th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-cartesian-therapeutics-rnac-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-cartesian-therapeutics-rnac-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"1111034348","title":"Top Calls on Wall Street: Nvidia, Applied Materials, Nu Holdings, Lowe's, Shake Shack, Gap & More","url":"https://stock-news.laohu8.com/highlight/detail?id=1111034348","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111034348?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:17","pubTimestamp":1763137069,"startTime":"0","endTime":"0","summary":"Here are the biggest calls on Wall Street on Friday:Susquehanna raised $Nu Holdings Ltd(NU)$ price target from $17 to $19. Susquehanna analyst James Friedman maintained a Positive rating. Nu Holdings...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GAP","NU","NVDA","RNAC","SHAK","ORIC","LOW","AMAT"],"gpt_icon":1},{"id":"2583350076","title":"Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2583350076","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583350076?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:45","pubTimestamp":1763135123,"startTime":"0","endTime":"0","summary":"Analyst Gil Blum of Needham maintained a Buy rating on Cartesian Therapeutics, retaining the price target of $40.00. Gil Blum’s rating is based on ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-realignment-boosts-cartesian-therapeutics-prospects-gil-blum-issues-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-realignment-boosts-cartesian-therapeutics-prospects-gil-blum-issues-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2583099575","title":"Cartesian Therapeutics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2583099575","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583099575?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:21","pubTimestamp":1763126460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 08:21 ET (13:21 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2583497505","title":"Cartesian Therapeutics price target raised to $44 from $42 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2583497505","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583497505?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:30","pubTimestamp":1763123428,"startTime":"0","endTime":"0","summary":"BTIG raised the firm’s price target on Cartesian Therapeutics (RNAC) to $44 from $42 and keeps a Buy rating on the shares. The firm cites the compa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-price-target-raised-to-44-from-42-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-price-target-raised-to-44-from-42-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2583523971","title":"Cartesian Therapeutics Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583523971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583523971?lang=en_us&edition=fundamental","pubTime":"2025-11-14 12:12","pubTimestamp":1763093575,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics, Inc. ( ($RNAC) ) has released its Q3 earnings. Here is a breakdown of the information Cartesian Therapeutics, Inc. presente...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2583951734","title":"Cartesian Therapeutics Reports Promising Phase 2 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583951734","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583951734?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:35","pubTimestamp":1763069710,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics ( ($RNAC) ) has shared an announcement. On November 13, 2025, Cartesian Therapeutics announced promising initial data from i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-reports-promising-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-reports-promising-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2583831514","title":"Cartesian Therapeutics Inc - Cartesian Plans to Pause Further Development of Descartes-08 in Sle","url":"https://stock-news.laohu8.com/highlight/detail?id=2583831514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583831514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067905,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUABFMZPX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2583514839","title":"Cartesian: Myositis Seamless Adaptive Clinical Trial Design Provides Potential Opportunity for Single Pivotal Trial Expected to Commence in 1H26","url":"https://stock-news.laohu8.com/highlight/detail?id=2583514839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583514839?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUABFMZPX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2583511265","title":"Cartesian - 100% Lldas Response Rate Observed in Patients With Sle Who Got Descartes-08 in Phase 2 Open-Label Trial Reaching Month 3 Follow-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2583511265","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583511265?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUABFMZPX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2583951452","title":"Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2583951452","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583951452?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067900,"startTime":"0","endTime":"0","summary":"100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187838/0/en/Cartesian-Therapeutics-Announces-Strong-Efficacy-Signal-in-Phase-2-Trial-of-Descartes-08-in-Patients-with-SLE-and-Expansion-of-Clinical-Development-into-Myositis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4139","DSGX","IE00B7SZL793.SGD","BK4187","CRS","IE00B66KJ199.SGD","SLE","RNAC","BK4006","IE0031619046.USD","BK4023","LU0963586101.USD","MG","BK4123","IE00B19Z4B17.USD","LU2065731478.USD","IE0009354923.USD"],"gpt_icon":0},{"id":"2582500743","title":"Recent 11% pullback would hurt Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders","url":"https://stock-news.laohu8.com/highlight/detail?id=2582500743","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582500743?lang=en_us&edition=fundamental","pubTime":"2025-11-11 18:27","pubTimestamp":1762856833,"startTime":"0","endTime":"0","summary":"Key Insights Significant insider control over Cartesian Therapeutics implies vested interests in company growth The top...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rnac/cartesian-therapeutics/news/recent-11-pullback-would-hurt-cartesian-therapeutics-inc-nas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rnac/cartesian-therapeutics/news/recent-11-pullback-would-hurt-cartesian-therapeutics-inc-nas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SQQQ","BK4139","USJW.SI","TSYW.SI",".IXIC","QLD","USAW.SI","PSQ","NVIW.SI","RNAC","QID","NQmain","MNQmain","TQQQ"],"gpt_icon":1},{"id":"2581988286","title":"Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Cartesian Therapeutics (RNAC) and Anixa Biosciences (ANIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581988286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581988286?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:30","pubTimestamp":1762529427,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Doximity (DOCS – Research Report), Cartesian Thera...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-doximity-docs-cartesian-therapeutics-rnac-and-anixa-biosciences-anix-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-doximity-docs-cartesian-therapeutics-rnac-and-anixa-biosciences-anix-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XLV","LABU","BK4585","RNAC","BK4167","HCSG","DOCS","ANIX","XBI","LU0128526141.USD","BK4613","BK4539","BK4588","BK4139","LU0029874061.USD","BK4581","BK4551"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}